[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"imatinib-therapy-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:imatinib-therapy-response":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100648802","hyperpolarized-mri-for-gist-on-imatinib-100648802",false,"NCT07724626","Hyperpolarized MRI for GIST on Imatinib","Integrated Precision Imaging for GIST Patients on Imatinib Therapy: Combining Hyperpolarized 13C-MRI, Metabolomics, and Radiomics","DNP_GIST","Inclusion Criteria:\n\n1. Patients with biopsy proved GIST.\n2. Patents will undergo imatinib.\n3. Patients have measurable disease on imaging study.\n4. Patients more than 18-year-old.\n\nExclusion Criteria:\n\n1. Pregnant or breast-feeding women.\n2. Contraindication to MRI study (e.g., claustrophobia or non-removable devices or implants that are incompatible with MRI).\n3. Intercurrent illness that will affect the compliance of the patient during the MRI study (e.g., active infection, symptomatic congestive heart failure, uncontrollable angina, arrhythmia, psychiatric disorders, dyspnea, or diarrhea).\n4. Severe hepatic dysfunction (alkaline phosphatase\u002Faspartate aminotransferase\u002Falanine aminotransferase \\>20 × upper limit of normal \\[ULN\\] or bilirubin \\> 10 × ULN).\n5. Severe renal impairment (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2).",true,"ALL","18 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","Conventional imaging methods, such as CT and MRI, are limited in evaluating GIST response to imatinib, as they mainly reflect tumor size and fail to capture early metabolic or molecular changes. This study investigates GISTs from a metabolic perspective by integrating hyperpolarized (HP) 13C-MRI, metabolomics, and radiomics. HP 13C-MRI enables real-time monitoring of metabolic flux in vivo, while NMR-based metabolomics provides systemic insights. In this single-center, prospective observational cohort study, 30 GIST patients receiving imatinib will undergo pre-treatment CT, HP 13C-MRI, metabolomics, and biopsy. Early response will be assessed at one month, with routine evaluation at four months. Patients will be categorized as responders or non-responders, and multi-omics data will be analyzed using machine learning. The study hypothesizes that metabolic changes detected by HP 13C-MRI can predict treatment response, offering reproducible, quantifiable metrics to improve evaluation and patient care.",[26,27],"Imatinib Therapy Response","Gastrointestinal Stromal Tumor (GIST)",[27,29,30,31,32],"Imatinib Therapy","Hyperpolarized 13C-MRI","Dynamic Nuclear Polarization (DNP)","Radiomics","NOT_YET_RECRUITING","2026-07-21",{"date":36,"type":37},"2026-07-24","ACTUAL",{"date":39,"type":22},"2027-01-01",{"date":41,"type":22},"2028-10-31",{"name":43,"class":44},"Chang Gung Memorial Hospital","OTHER"]